Last Price$89.69NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/23/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$87.80 (1)
Ask (Size)$89.69 (77)
Day Low / HighN/A - N/A
Volume652.0 K

Incyte Releases Positive Results of Phase 2 Study of Cancer Drug Retifanlimab

6:27AM ET 9/18/2020 MT Newswires
Incyte (INCY) on Friday released results of a phase 2 study of retifanlimab in previously treated patients with advanced squamous cell carcinoma of the anal canal demonstrating the potential of the drug candidate to provide treatment.

The results of the study showed a confirmed objective response rate of 14%. Patients with metastatic squamous cell carcinoma have poor five-year survival and there are no standard treatment for patients who have progressed after chemotherapy, according to a news release.

The drug candidate was also found to be well-tolerated.

Price: 90.42, Change: +0.48, Percent Change: +0.53